why choose us

First received: October 05, 2022

Clinical Trial: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed or Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multipl

Brief Summary: The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

Read more